Research ArticleCancer

Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolence

See allHide authors and affiliations

Science Translational Medicine  14 Feb 2018:
Vol. 10, Issue 428, eaal1571
DOI: 10.1126/scitranslmed.aal1571

Interrupting IL-23 signaling could curb CLL

Chronic lymphocytic leukemia (CLL) cells are derived from B cells, but the exact signals that drive their expansion and survival are not completely understood. Cutrona et al. observed differential expression of the IL-23 receptor on biopsies from early-stage CLL patients, and higher expression was associated with poor prognosis. CLL cells could also produce IL-23 in vitro. The authors reasoned that the cells could produce and respond to this cytokine in a survival feedback loop and demonstrated that an anti–IL-23 antibody could slow tumor growth in a xenograft mouse model. These promising results could open up new avenues of treatment for CLL.

View Full Text

Stay Connected to Science Translational Medicine